Elizabeth C. Mormino, Sarah A. Biber, Annalise Rahman-Filipiak, Konstantinos Arfanakis, Lindsay Clark, Jeffrey L. Dage, John A. Detre, Bradford C. Dickerson, Michael C. Donohue, Steven Kecskemeti, Timothy J. Hohman, William J. Jagust, Dirk C. Keene, Walter Kukull, Swati R. Levendovszky, Howie Rosen, Paul M. Thompson, Victor L. Villemagne, David A. Wolk, Ozioma C. Okonkwo, Gil D. Rabinvovici, Monica Rivera-Mindt, Tatiana Foroud, Sterling C. Johnson
{"title":"The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)","authors":"Elizabeth C. Mormino, Sarah A. Biber, Annalise Rahman-Filipiak, Konstantinos Arfanakis, Lindsay Clark, Jeffrey L. Dage, John A. Detre, Bradford C. Dickerson, Michael C. Donohue, Steven Kecskemeti, Timothy J. Hohman, William J. Jagust, Dirk C. Keene, Walter Kukull, Swati R. Levendovszky, Howie Rosen, Paul M. Thompson, Victor L. Villemagne, David A. Wolk, Ozioma C. Okonkwo, Gil D. Rabinvovici, Monica Rivera-Mindt, Tatiana Foroud, Sterling C. Johnson","doi":"10.1002/alz.14383","DOIUrl":null,"url":null,"abstract":"The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address this gap. The ADRCs longitudinally follow ≈ 17,000 participants, ranging from cognitively unimpaired to dementia, arising from Alzheimer's disease (AD) and related dementias (ADRD; e.g., AD, Lewy body disorders, vascular). Motivated by the Alzheimer's Disease Neuroimaging Initiative's (ADNI) impact, the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) was formed. Leveraging existing ADRC infrastructure, CLARiTI will integrate standardized imaging and plasma collection to characterize mixed pathologies and use community-engaged research methods to ensure that ≥ 25% of the sample is from underrepresented populations (e.g., ethnoculturally minoritized, low education). The resulting ADRD profiles, within a more diverse sample, will provide key resources for ADRCs and an unprecedented, more generalizable publicly available imaging-plasma dataset.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"244 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14383","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address this gap. The ADRCs longitudinally follow ≈ 17,000 participants, ranging from cognitively unimpaired to dementia, arising from Alzheimer's disease (AD) and related dementias (ADRD; e.g., AD, Lewy body disorders, vascular). Motivated by the Alzheimer's Disease Neuroimaging Initiative's (ADNI) impact, the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) was formed. Leveraging existing ADRC infrastructure, CLARiTI will integrate standardized imaging and plasma collection to characterize mixed pathologies and use community-engaged research methods to ensure that ≥ 25% of the sample is from underrepresented populations (e.g., ethnoculturally minoritized, low education). The resulting ADRD profiles, within a more diverse sample, will provide key resources for ADRCs and an unprecedented, more generalizable publicly available imaging-plasma dataset.
期刊介绍:
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.